An AI Drug Company Named a Candidate for Dry Macular Degeneration, and the Target Is Undisclosed

Insilico Medicine announced on August 5 the nomination of ISM9077 as a preclinical candidate for ocular diseases including dry AMD, uveitis and dry eye disease. What a Preclinical Candidate Designation Actually IsThe term sounds official and is not, which is the single most useful thing for a reader to understand. Inside a pharmaceutical company, drug discovery moves through stages. A new preclinical candidate joins a crowded early pipeline where most entrants will not succeed. Insilico Medicine nominated ISM9077 as a preclinical candidate for ocular diseases including dry AMD, uveitis, and dry eye disease.